276 related articles for article (PubMed ID: 23280583)
21. Dual role of IL-12 in the therapeutic efficacy or failure during combined PEG-Interferon-α2A and ribavirin therapy in patients with chronic hepatitis C.
Araújo AR; Peruhype-Magalhães V; Coelho-dos-Reis JG; Chaves LP; de Lima TA; Pimentel JP; de Paula L; de Almeida CM; Tarragô AM; Tateno A; Levi JE; Teixeira-Carvalho A; Martins-Filho OA; Lira Eda F; Torres KL; Talhari S; Malheiro A
Immunol Lett; 2013; 154(1-2):61-9. PubMed ID: 23973662
[TBL] [Abstract][Full Text] [Related]
22. The magnitude of week 4 HCV RNA decay on pegylated interferon/ribavirin accurately predicts virological failure in patients with genotype 1.
Bárcena R; Moreno A; del Campo S; Muriel A; Mateos ML; Garrido E; García M; Quereda C; Moreno S; Moreno A
Antivir Ther; 2007; 12(3):401-6. PubMed ID: 17591030
[TBL] [Abstract][Full Text] [Related]
23. Viral kinetic of HCV genotype-4 during pegylated interferon alpha 2a: ribavirin therapy.
Derbala MF; El Dweik NZ; Al Kaabi SR; Al-Marri AD; Pasic F; Bener AB; Shebl FM; Amer AM; Butt MT; Yakoob R; John A; Al Mohanadi M; Al Khinji MA
J Viral Hepat; 2008 Aug; 15(8):591-9. PubMed ID: 18482284
[TBL] [Abstract][Full Text] [Related]
24. Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin.
Soriano V; Núñez M; Camino N; Maida I; Barreiro P; Romero M; Martin-Carbonero L; Garcia-Samaniego J; González-Lahoz J
Antivir Ther; 2004 Aug; 9(4):505-9. PubMed ID: 15456081
[TBL] [Abstract][Full Text] [Related]
25. Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C.
Cramp ME; Rossol S; Chokshi S; Carucci P; Williams R; Naoumov NV
Gastroenterology; 2000 Feb; 118(2):346-55. PubMed ID: 10648463
[TBL] [Abstract][Full Text] [Related]
26. Usefulness of a new immunoradiometric assay of HCV core antigen to predict virological response during PEG-IFN/RBV combination therapy for chronic hepatitis with high viral load of serum HCV RNA genotype 1b.
Sasase N; Kim SR; Kim KI; Taniguchi M; Imoto S; Mita K; Hotta H; Shouji I; El-Shamy A; Kawada N; Kudo M; Hayashi Y
Intervirology; 2008; 51 Suppl 1():70-5. PubMed ID: 18544951
[TBL] [Abstract][Full Text] [Related]
27. Increased baseline proinflammatory cytokine production in chronic hepatitis C patients with rapid virological response to peginterferon plus ribavirin.
Par G; Szereday L; Berki T; Palinkas L; Halasz M; Miseta A; Hegedus G; Szekeres-Bartho J; Vincze A; Hunyady B; Par A
PLoS One; 2013; 8(7):e67770. PubMed ID: 23874444
[TBL] [Abstract][Full Text] [Related]
28. Hepatitis C virus viral kinetics during α-2a or α-2b pegylated interferon plus ribavirin therapy in liver transplant recipients with different immunosuppression regimes.
Berenguer M; Ortíz-Cantó C; Abellán JJ; Aguilera V; Rubín A; Prieto M; López-Labrador FX
J Clin Virol; 2012 Mar; 53(3):231-8. PubMed ID: 22222052
[TBL] [Abstract][Full Text] [Related]
29. IFN-stimulated gene expression is a useful potential molecular marker of response to antiviral treatment with Peg-IFNα 2b and ribavirin in patients with hepatitis C virus genotype 1.
Sixtos-Alonso MS; Sánchez-Muñoz F; Sánchez-Ávila JF; Martínez RA; Domínguez López A; Vargas Vorácková F; Uribe M
Arch Med Res; 2011 Jan; 42(1):28-33. PubMed ID: 21376259
[TBL] [Abstract][Full Text] [Related]
30. Lack of rapid virological response predicts interferon-alpha2b/ribavirin therapy failure in HCV genotype 2 patients: a single-centre study.
Rumi MG; Aghemo A; D'Ambrosio R; Ronchi G; Del Ninno E; Gallus S; Colombo M
Antivir Ther; 2007; 12(7):1033-40. PubMed ID: 18018761
[TBL] [Abstract][Full Text] [Related]
31. Enhanced efficacy of pegylated interferon alpha-2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomized trial and quality of life analysis.
Kamal SM; Ahmed A; Mahmoud S; Nabegh L; El Gohary I; Obadan I; Hafez T; Ghoraba D; Aziz AA; Metaoei M
Liver Int; 2011 Mar; 31(3):401-11. PubMed ID: 21281434
[TBL] [Abstract][Full Text] [Related]
32. Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C.
Napoli N; Giannelli G; Parisi CV; Antonaci A; Maddalena G; Antonaci S
New Microbiol; 2005 Jan; 28(1):13-21. PubMed ID: 15782622
[TBL] [Abstract][Full Text] [Related]
33. Intrahepatic mRNA levels of interferon gamma and tumor necrosis factor alpha and response to antiviral treatment of chronic hepatitis C.
Dumoulin FL; Wennrich U; Nischalke HD; Leifeld L; Fischer HP; Sauerbruch T; Spengler U
J Hum Virol; 2001; 4(4):195-9. PubMed ID: 11694847
[TBL] [Abstract][Full Text] [Related]
34. Simeprevir (TMC435) with pegylated interferon/ribavirin in patients coinfected with HCV genotype 1 and HIV-1: a phase 3 study.
Dieterich D; Rockstroh JK; Orkin C; Gutiérrez F; Klein MB; Reynes J; Shukla U; Jenkins A; Lenz O; Ouwerkerk-Mahadevan S; Peeters M; De La Rosa G; Tambuyzer L; Jessner W
Clin Infect Dis; 2014 Dec; 59(11):1579-87. PubMed ID: 25192745
[TBL] [Abstract][Full Text] [Related]
35. Pegylated interferon plus ribavirin combination therapy for chronic hepatitis C with high viral load of serum hepatitis C virus RNA, genotype 1b, discontinued on attaining sustained virological response at week 16 after onset of acute pancreatitis.
Kim SR; Imoto S; Mita K; Taniguchi M; Sasase N; Muramatsu A; Kudo M; Kitai S; El-Shamy A; Hotta H; Hayashi Y
Digestion; 2009; 79(1):36-9. PubMed ID: 19246919
[TBL] [Abstract][Full Text] [Related]
36. Monocyte-derived dendritic cells in children with chronic hepatitis C: correlation with interferon and ribavirin therapy.
Khedr MA; E Behairy B; Hussein ME; Marei AM; Nage SA; Zakaria HM
Eur J Gastroenterol Hepatol; 2015 Oct; 27(10):1170-4. PubMed ID: 26148246
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of peg-IFN alfa-2a with ribavirin for the treatment of HCV/HIV coinfected patients who failed previous IFN based therapy.
Rodríguez-Torres M; Rodríguez-Orengo JF; Ríos-Bedoya CF; Fernández-Carbia A; González-Lassalle E; Salgado-Mercado R; Marxuach-Cuétara AM
J Clin Virol; 2007 Jan; 38(1):32-8. PubMed ID: 17064957
[TBL] [Abstract][Full Text] [Related]
38. Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir.
Vispo E; Barreiro P; Pineda JA; Mira JA; Maida I; Martín-Carbonero L; Rodríguez-Nóvoa S; Santos I; López-Cortes LF; Merino D; Rivero A; Soriano V
Antivir Ther; 2008; 13(3):429-37. PubMed ID: 18572756
[TBL] [Abstract][Full Text] [Related]
39. Impact of ribavirin plasma level on sustained virological response in patients treated with pegylated interferon and ribavirin for chronic hepatitis C.
Breilh D; Foucher J; Castéra L; Trimoulet P; Djabarouti S; Merrouche W; Couzigou P; Saux MC; de Lédinghen V
Aliment Pharmacol Ther; 2009 Sep; 30(5):487-94. PubMed ID: 19523176
[TBL] [Abstract][Full Text] [Related]
40. Prolonged PEG-IFN and RBV is effective in patients with HCV genotype 1 and high viral load who achieved virological response later than 24 weeks.
Ueda T; Chung H; Kudo M; Ishikawa E; Hayaishi S; Tatsumi C; Inoue T; Yada N; Hagiwara S; Minami Y; Ueshima K
Intervirology; 2010; 53(1):55-9. PubMed ID: 20068342
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]